Table 2

Profile of serum autoantibodies

Patient number	Age and gender	Diagnosis	Anti-NR2	Antiribosomal P	Anti-NR1/NR2
1	50 F	ACS	154	12	− (negative)
2	53 F	ACS	824	38	−
3	33 F	ACS	38	0	−
4	28 M	ACS	30	144	−
5	23 F	ACS	24	550	−
6	14 F	ACS	284	512	−
7	66 F	ACS	54	3094	−
8	39 M	ACS	88	4	−
9	51 F	ACS	34	12	−
10	65 F	ACS	34	916	1:40 (positive)
11	32 F	ACS	32	12	−
12	46 F	ACS	1320	0	−
13	30 F	ACS+myelitis	142	0	−
14	34 F	ACS	166	508	−
15	19 F	ACS	144	28	−
16	42 F	ACS+myelitis	140	0	−
17	37 F	ACS	616	360	−
18	39 F	Anx	30	6	−
19	65 F	Cog	78	6	−
20	43 F	Psy	672	34	1:80 (positive)
21	37 F	Psy	48	70	−
22	17 F	Psy	126	612	−
23	71 F	Seizure	240	58	−
24	22 F	Seizure	70	6	−
25	40 F	Seizure	40	12	−
26	33 F	Demyelinating	34	4	−
27	42 F	CVD	40	8	−
28	44 F	Seizure	90	12	−
29	60 F	Seizure	40	1728	−
30	32F	Peripheral	80	22	−
31	39 F	Headache	26	10	−

Patients 1–22: diffuse NPSLE.
Patients 23–31: focal NPSLE.
Bold figures denote positive results for anti-NR2 and antiribosomal P by ELISA.
ACS, acute confusional state; anx, anxiety disorder; Cog, cognitive dysfunction; CVD, cerebrovascular disease.; F, female; M, male; psy, psychosis.